查看犬血管肉瘤化疗管理 – 更新的源代码

== Abstract ==

血管肉瘤是一种累及犬科动物的恶性血管内皮肿瘤。它通常影响老年动物，并且还具有某些品种偏好的特征。脾脏是犬科动物最常受影响的器官，但皮肤相关的血管肉瘤较少见。血管肉瘤等恶性肿瘤的治疗应基于多模式疗法，该疗法结合了手术切除、化疗、放疗和免疫疗法等不同技术。尽管几种化疗药物可以单独使用或联合使用，但它在产生预期的生存期增加方面是无效的。发现紫杉醇和白藜芦醇等较新的药物在体外对血管肉瘤细胞系有效。但需要进一步的研究来评估这种化疗药物的体内效应。应进行进一步的研究，以确定有效的化疗药物，如紫杉醇和白藜芦醇，这些药物可用于临床治疗犬血管肉瘤，而没有任何副作用。

Hemangiosarcoma is a malignant vascular endothelial tumor affecting canines. It commonly affects older animals and is also characterized by certain breed predilection. Spleen is the most commonly affected organ in canines but skin associated hemangiosarcomas are less frequent. Management of malignant tumors like hemangiosarcoma should be based on multimodal therapy that combines different techniques like surgical excision, chemotherapy, radiation therapy, and immunotherapy. Even though several chemotherapeutic agents are used alone or as in combinations, it was ineffective in producing a desirable increase in the survival period. Newer agents like Paclitaxel and Resveratrol was found to be effective against hemangiosarcoma cell lines in-vitro. But further studies are required for evaluating the in-vivo effects of such chemotherapeutic agents. Further research should be directed to identify effective chemotherapeutic agents like Paclitaxel and Resveratrol that can be used to manage canine hemangiosarcoma clinically without any side effects.

<br>